Strategic report Governance & remuneration Financial statements Investor information Pipeline, products and competition Pharmaceuticals and Vaccines product development pipeline Key In-licence or other alliance relationship with third party S Month of first submission ViiV Healthcare, a global specialist HIV company with GSK, BLA Biological Licence Application Pzer, Inc. and Shionogi Limited as shareholders, is responsible MAA Marketing Authorisation Application Europe for developing and delivering HIV medicines.
NDA New Drug Application US Also being developed for indications in another therapeutic area Phase I Evaluation of clinical pharmacology, usually conducted in volunteers 1 Option-based alliance with Ionis Pharmaceuticals Phase II Determination of dose and initial evaluation of efcacy, conducted in a 2 Option-based alliance with Adaptimmune Ltd. small number of patients 3 Option-based alliance with OncoMed Pharmaceuticals Phase III Large comparative study compound versus placebo and or est ablished 4 Option-based alliance with Telethon and Ospedale San Raffaele treatment in patients to establish clinical benefit and safety 5 Option-based alliance with Valneva MAA and NDA BLA regulatory review milestones shown in the table below are those that have been achieved.
Future ling dates are not included in this list.
Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA HIV and Infectious Diseases dolutegravir HIV integrase inhibitor non-nucleoside HIV infections two drug maintenance regimen III rilpivirine reverse transcriptase inhibitor NNRTI 3684934 HIV attachment inhibitor HIV infections III tafenoquine 8-aminoquinoline Plasmodium vivax malaria III Relenza i. v. neuraminidase inhibitor i. v. inuenza III cabotegravir HIV integrase inhibitor long-acting HIV pre-exposure prophylaxis II parenteral formulation cabotegravir HIV integrase inhibitor non-nucleoside HIV infections II rilpivirine reverse transcriptase inhibitor NNRTI long-acting parenteral formulations gepotidacin type 2 topoisomerase inhibitor bacterial infections II 2140944 danirixin chemokine C-X-C Motif receptor 2 inuenza II CXCR2 antagonist 3532795 HIV maturation inhibitor HIV infections II 2838232 HIV maturation inhibitor HIV infections I 1 3228836 HBV antisense oligonucleotide hepatitis B I 1 3389404 HBV LICA antisense oligonucleotide hepatitis B I 2878175 nonstructural protein 5B NS5B hepatitis C I polymerase inhibitor Respiratory uticasone furoate glucocorticoid agonist long-acting beta2 chronic obstructive pulmonary disease COPD III vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin 5 IL5 monoclonal antibody COPD III 961081 muscarinic acetylcholine antagonist, beta2 COPD II agonist MABA 961081 muscarinic acetylcholine antagonist, beta2 COPD II uticasone furoate agonist MABA glucocorticoid agonist 2245035 toll-like receptor 7 TLR7 agonist asthma II 2269557 phosphatidylinositol 3-kinase delta PI3K asthma and COPD II inhibitor 2586881 recombinant human angiotensin converting acute lung injury II enzyme 2 rhACE2 2862277 tumour necrosis factor receptor-1 TNFR1 acute lung injury II domain antibody danirixin chemokine C-X-C Motif receptor 2 CXCR2 COPD II antagonist uticasone furoate glucocorticoid agonist long-acting beta2 asthma II vilanterol agonist muscarinic acetylcholine umeclidinium antagonist losmapimod p38 kinase inhibitor COPD II mepolizumab interleukin 5 IL5 monoclonal antibody nasal polyposis II mepolizumab interleukin 5 IL5 monoclonal antibody hypereosinophilic syndrome II sirukumab interleukin 6 IL6 human monoclonal antibody severe asthma II 3008348 alpha V beta 6 integrin antagonist idiopathic pulmonary brosis I GSK Annual Report 2015 225 Strategic report Governance & remuneration Financial statements Investor information Pipeline, products and competition continued Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Oncology 2 3377794 NY-ESO-1 autologous engineered sarcoma, multiple myeloma, non-small cell lung II TCR-T cells engineered TCR cancer, melanoma and ovarian cancer 3 tarextumab notch 2 3 monoclonal antibody small cell lung cancer II 3 brontictuzumab notch 1 monoclonal antibody solid tumours and haematological malignancies I 3174998 OX40 agonist monoclonal antibody solid tumours and haematological malignancies I 2879552 lysine-specic demethylase 1 LSD1 acute myeloid leukemia and small cell lung cancer I inhibitor 2857916 beta cell maturation antigen antibody multiple myeloma I drug conjugate 2849330 erb-b2 receptor tyrosine kinase 3 solid tumours I ErbB3 monoclonal antibody 2816126 enhancer of zeste homologue2 solid tumours and haematological malignancies I EZH2 inhibitor 2636771 phosphatidylinositol 3-kinase castration resistant prostate cancer I PI3K beta inhibitor 2256098 focal adhesion kinase inhibitor mesothelioma I 525762 BET family bromodomain inhibitor solid tumours and haematological malignancies I Immuno-inammation sirukumab interleukin 6 IL6 human monoclonal rheumatoid arthritis III antibody sirukumab interleukin 6 IL6 human monoclonal giant cell arteritis III antibody Benlysta B lymphocyte stimulator monoclonal systemic lupus erythematosus III antibody s. c. Benlysta B lymphocyte stimulator monoclonal vasculitis III antibody i. v. Benlysta B lymphocyte stimulator monoclonal transplant rejection II antibody i. v. Benlysta Rituxan B lymphocyte stimulator monoclonal Sjogren's syndrome II antibody s. c. cluster of differentiation 20 CD20 monoclonal antibody i. v. 3196165 granulocyte macrophage colonyrheumatoid arthritis II stimulating factor monoclonal antibody 2330811 oncostatin M OSM monoclonal antibody systemic sclerosis I 2618960 interleukin 7 IL7 receptor monoclonal Sjogren's syndrome I antibody 2646264 spleen tyrosine kinase Syk inhibitor chronic urticaria I topical 2831781 lymphocyte activation gene 3 LAG3 autoimmune disease I protein monoclonal antibody 2982772 receptor-interacting protein 1 RIP1 psoriasis, rheumatoid arthritis and ulcerative colitis I kinase inhibitor 3050002 chemokine C-C motif ligand 20 psoriatic arthritis I CCL20 monoclonal antibody 3117391 macrophage targeted histone rheumatoid arthritis I deacetylase inhibitor 3179106 rearranged during transfection RET inammatory disorders of the bowel I kinase inhibitor Rare diseases 2696273 ex-vivo stem cell gene therapy adenosine deaminase severe combined immune Submitted S: May15 deficiency ADA-SCID 1 2998728 transthyretin TTR production inhibitor  amyloidosis III mepolizumab interleukin 5 IL5 monoclonal antibody eosinophilic granulomatosis with polyangiitis III 2398852 2315698 serum amyloid P component SAP amyloidosis II monoclonal antibody SAP depleter CPHPC 2696274 ex-vivo stem cell gene therapy metachromatic leukodystrophy II 2696275 ex-vivo stem cell gene therapy Wiscott-Aldrich syndrome II 4 2696277 ex-vivo stem cell gene therapy beta-thalassemia I 226 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Vaccines Shingrix recombinant Herpes Zoster prophylaxis III Zoster Vaccine MMR live attenuated measles, mumps, rubella prophylaxis III US N A Ebola recombinant viral vector Ebola haemorrhagic fever prophylaxis II Group B conjugated Group B streptococcus prophylaxis II Streptococcus maternal immunisation S. pneumoniae next recombinant conjugated Streptococcus pneumoniae disease prophylaxis II generation COPD recombinant reduction of the frequency of COPD exacerbations II associated with non-typeable Haemophilus inuenzae and Moraxella catarrhalis Hepatitis C recombinant viral vector hepatitis C virus prophylaxis II Malaria next generation recombinant malaria prophylaxis Plasmodium falciparum II Men ABCWY recombinant conjugated meningococcal A, B, C, W and Y disease prophylaxis II in adolescents 5 Pseudomonas recombinant pseudomonas infection prophylaxis II Shigella conjugated and outer membrane Shigella diarrhea prophylaxis II Tuberculosis recombinant tuberculosis prophylaxis II RSV recombinant respiratory syncytial virus prophylaxis II maternal immunisation RSV  recombinant respiratory syncytial virus prophylaxis I viral vector HIV recombinant proteins HIV infection prophylaxis I Other pharmaceuticals Metabolic retosiban oxytocin antagonist spontaneous pre-term labour III daprodustat 1278863 prolyl hydroxylase inhibitor anaemia associated with chronic renal disease II 2330672 ileal bile acid transport IBAT inhibitor cholestatic pruritus II camicinal motilin receptor agonist delayed gastric emptying II Eperzan Tanzeum glucagon-like peptide 1 GLP1 type 1 diabetes II albiglutide receptor agonist losmapimod p38 kinase inhibitor focal segmental glomerular sclerosis II otelixizumab cluster of differentiation 3 CD3 new onset type 1 diabetes II daprodustat 1278863 prolyl hydroxylase inhibitor topical wound healing I monoclonal antibody 2798745 transient receptor potential cation heart failure I channel V4 TRPV4 antagonist 2881078 selective androgen receptor modulator muscle wasting I oxytocin inhaled oxytocin postpartum hemorrhage I Dermatology chlorhexidine cationic polybiguanide topical prevention of omphalitis Submitted S: Oct15 2894512 non-steroidal anti-inammatory topical atopic dermatitis II 2894512 non-steroidal anti-inammatory topical psoriasis II 2981278 ROR gamma inverse agonist topical psoriasis II umeclidinium muscarinic acetylcholine antagonist topical hyperhidrosis II mepolizumab interleukin 5 IL5 monoclonal antibody severe atopic dermatitis I Neurosciences 933776 beta amyloid monoclonal antibody geographic retinal atrophy II Benlysta B lymphocyte stimulator monoclonal myasthenia gravis II antibody i. v. rilapladib  phospholipase Alzheimer's disease II A2 Lp-PLA2 inhibitor n a ocular target LICA antisense geographic atrophy age-related macular disease I 1 oligonucleotide GSK Annual Report 2015 227 Strategic report Governance & remuneration Financial statements Investor information Pipeline, products and competition continued Pharmaceutical products, competition and intellectual property 3 Patent expiry dates Major Products Compounds Indication s competitor brands US EU Respiratory Anoro Ellipta umeclidinium bromide COPD Spiriva Handihaler 2025 2029 vilanterol terfenatate Respimat, Stiolto NCE NCE Spiolto Respimat 2027-2030 2022-2025 Ultibro Breezhaler, device device Duaklir Genuair formulation formulation Arnuity Ellipta uticasone furoate asthma Qvar, Pulmicort 2021 NA Asmanex, NCE Alvesco 2027-2030 device formulation 2 Avamys Veramyst uticasone furoate rhinitis Nasonex 2021 2023 Flixotide Flovent uticasone propionate asthma COPD Qvar, Singulair 2016 expired Diskus device Diskus device 1 2018-2026 2017 HFA-device HFA-device Incruse Ellipta umeclidinium bromide COPD Spiriva Handihaler 2025 2029 Respimat, NCE NCE Eklira Genuair 2027-2030 2022-2025 device device formulation formulation 4 4 Nucala mepolizumab severe eosinophilic asthma Xolair 2016 2020 Relvar Breo uticasone furoate asthma COPD Symbicort, Foster, 2022 2027 Ellipta vilanterol terfenatate Flutiform, Dulera NCE NCE 2027-2030 2022-2025 device device formulation formulation Seretide Advair salmeterol xinafoate asthma COPD Symbicort, Foster, 2016 expired uticasone propionate Flutiform, Dulera Diskus device Diskus device 1 2018-2026 2017 HFA-device HFA-device Serevent salmeterol xinafoate asthma COPD Foradil, Spiriva, 2016 expired Handihaler Respimat Diskus device Diskus device Onbrez 2019 HFA-device 1 Ventolin HFA albuterol sulphate asthma COPD generic companies 2018-2026 2017 HFA-device HFA-device Anti-virals Valtrex valaciclovir genital herpes, coldsores, Famvir expired expired shingles Zefx Epivir-HBV lamivudine chronic hepatitis B Hepsera expired expired Central nervous system Lamictal lamotrigine epilepsy, bipolar disorder Keppra, Dilantin expired expired Imigran Imitrex sumatriptan migraine Zomig, Maxalt, Relpax expired expired Seroxat Paxil paroxetine depression, various Effexor, Cymbalta, expired expired anxiety disorders Lexapro Cardiovascular and urogenital Eperzan Tanzeum albiglutide Type 2 diabetes Victoza, Byetta 2022 2027 Bydureon, Lyxumia Trulicity Avodart dutasteride benign prostatic hyperplasia Proscar, Flomax, expired 2017 nasteride 1,2 Coreg CR carvedilol phosphate mild-to-severe heart failure, Toprol XL 2026 NA hypertension, left ventricular formulation dysfunction post MI See Risk factors on page 232 for details of uncertainty on the timing of follow-on competition.
1 See Note 45 to the financial statements, Legal proceedings.
3 Includes Supplementary Protection Certicates and other patent term extensions, where granted.
4 Data exclusivity expires 2025 EU and 2027 US.
228 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Pharmaceutical products, competition and intellectual property continued 3 Patent expiry dates Major Products Compounds Indication s competitor brands US EU Anti-bacterials Augmentin amoxicillin clavulanate common bacterial generic products NA expired potassium infections Rare diseases Volibris ambrisentan pulmonary hypertension Tracleer, Revatio NA 2020 Immuno-inammation Benlysta belimumab systemic lupus erythematosus 2023 2026 HIV 1 1 Epzicom Kivexa lamivudine and abacavir HIV AIDS Truvada, Atripla 2016 2019 Stribild combination combination Complera Eviplera 1 Lexiva Telzir fosamprenavir HIV AIDS Prezista, Kaletra, 2018 2019 Reyataz Selzentry Celsentri maraviroc HIV AIDS Isentress, Intelence, 2021 2022 Prezista Tivicay dolutegravir HIV AIDS Isentress, Prezista 2027 2029 Reyataz, Kaletra Triumeq dolutegravir, lamivudine HIV AIDS Truvada, Atripla 2027 2031 and abacavir Stribild Complera Eviplera 1,2 Trizivir lamivudine, zidovudine HIV AIDS Truvada, Atripla 2016 2016 and abacavir Stribild combination combination Complera Eviplera Vaccines products, competition and intellectual property Patent expiry dates Major Products Compounds Indication s competitor brands US EU 1 Bexsero meningococcal group-B Meningitis group B prevention Trumenba 2027 2028 vaccine Boostrix diphtheria, tetanus, acellular diphtheria, tetanus, acellular Adacel 2017 2017 pertussis Pertussis booster vaccination Infanrix Hexa diphtheria, tetanus, pertussis, Prophylaxis against diphtheria, Pentacel, Pediacel, 2018 expired Pediarix polio, hepatitis B, tetanus, pertussis, polio, Pentaxim, Pentavac, Haemophilus inuenzae hepatitis B, Haemophilus Hexaxim type B EU inuenzae type B EU Cervarix HPV 16 & 18 virus like human papilloma virus Gardasil Silgard 2020 2020 particles VLPs, AS04 type 16 and 18 adjuvant MPL aluminium hydroxide Fluarix Tetra split inactivated inuenza seasonal inuenza Intenza, Flumist QIV, 2022 2022 virus subtypes A and prophylaxis Vaxigrip QIV, subtype B antigens Fluzone QIV, Fluzone High Dose FluLaval split inactivated inuenza seasonal inuenza Vaxigrip, Mutagrip, 2022 2022 virus subtypes A and prophylaxis Fluzone, Inuvac, subtype B antigens Aggripal, Fluad, Intenza, Flumist Menveo meningococcal group A, C, WMeningitis group A, C, W-135 Mencevax, Menactra 2025 2025 135 and Y conjugate vaccine and Y prophylaxis Prepandrix derived split inactivated pandemic H5N1 Aunov, Vepacel 2026 inuenza virus antigen, inuenza prophylaxis AS03 adjuvant Rotarix Human rotavirus RIX4414 strain Rotavirus prophylaxis Rotateq 2020 Synorix conjugated pneumococcal Prophylaxis against invasive Prevenar Prevnar NA 2024 polysaccharide disease, pneumonia, acute otitis media 1 See Note 45 to the financial statements, Legal proceedings.
GSK Annual Report 2015 229 Strategic report Governance & remuneration Financial statements Investor information Pipeline, products and competition continued Consumer Healthcare products and competition Brand Products Application Markets Competition Wellness Panadol and tablets, caplets, paracetamol-based global except US Advil, Pzer Panadol Cold infant syrup drops treatment for headache, Aspirin, Bayer & Flu joint pain, fever, Tylenol, Johnson & Johnson cold symptoms Voltaren topical gel non-steroidal, diclofenac global Advil, Pzer based anti-inammatory Aspirin, Bayer Tylenol, Johnson & Johnson Otrivin nasal spray nasal decongestant Germany, Poland, Afrin, Merck Russia, Sweden, Nasivin, Merck Ukraine Therau tablets and syrups cold and u relief Russia, Poland, Tylenol Cold & Flu, Ukraine, US Johnson & Johnson Mucinex, Reckitt Benckiser Lemsip, Reckitt Benckiser Flonase nasal spray allergy relief China, Ireland, Claritin, Bayer Flixanase UK, US Rhinocort, Astra Zeneca Flixonase Nasacort, Sano Piriteze ENO effervescent immediate relief antacid global except US Estomazil, Hypermarca Gelusil, Pzer Tums chewable tablets immediate relief antacid US Alka-Seltzer, Bayer Gaviscon, Reckitt Benckiser Rolaids, Sano Nicorette US, lozenges, gum and treatment of nicotine global Nicorette, Johnson & Johnson NicoDerm, trans-dermal patches withdrawal as an aid to NiQuitin, Perrigo Nicotinell smoking reduction and ex.
Australia cessation Oral health Sensodyne, toothpastes, toothbrushes, relief of dentinal global Colgate Sensitive Pro-Relief, Pronamel mouth rinse hypersensitivity.
Colgate-Palmolive Pronamel additionally Elmex, Colgate-Palmolive protects against acid Oral B, Procter & Gamble erosion Parodontax toothpaste, helps prevent bleeding Germany, Ireland Colgate Total Gum Health, Corsodyl medicated mouthwash, gums, treats and prevents Italy, United Kingdom Colgate-Palmolive gel and spray gingivitis Yunnan Baiyao, State Enterprise China Polident, denture adhesive, denture improve retention and global Fixodent and Kukident, Poligrip, cleanser comfort of dentures, Procter & Gamble, Corega cleans dentures Steradent, Reckitt Benckiser Aquafresh toothpastes, toothbrushes aids prevention of dental global Colgate, Colgate-Palmolive mouthwashes cavities, maintains healthy Crest, Procter & Gamble teeth, gums and fresh breath Oral-B, Procter & Gamble Skin health Zovirax topical cream and lip care to treat and prevent global Compeed, Johnson & Johnson Abreva non-medicated patch the onset of cold sores Carmex, Carma Labs Blistex, Blistex Incorporated retail own label Nutrition Horlicks malted drinks and foods nutritional Indian sub-continent, Bournvita, Mondelez beverages & food United Kingdom, Ireland Complan, Heinz 230 GSK Annual Report 2015
